Filing Signals

Source: SEC EDGAR Compiled 2026-08-23 04:41 UTC Unattended

← All events

CHINA PHARMA HOLDINGS, INC.

CIK 1106644 CPHI·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Going concern 10-Q
  2. Accounting policy change 10-Q
Going concern Filing comparison

CHINA PHARMA HOLDINGS, INC. no longer discloses a going-concern conclusion

Substantial doubt raised, alleviated by management's plans → No going-concern disclosure

Evidence
Caveat
None
Comparable
True
Current state
none
Current state label
No going-concern disclosure
Direction
eased
Located in
Prior filed
2026-05-15
Prior form
10-Q
Prior state
doubt_alleviated
Prior state label
Substantial doubt raised, alleviated by management's plans
Registrant changed from
None
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Accounting policy change Filing comparison

CHINA PHARMA HOLDINGS, INC. referenced accounting standard ASU 2016-13 for the first time

The Company adopted ASU 2016-13 Financial Instruments — Credit Losses (ASC Topic 326): Measurement of Credit Losses on Financial Instruments, which replaced the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology.
Evidence
Adopted
['2016-13']
Contexts
['The Company adopted ASU 2016-13 Financial Instruments — Credit Losses (ASC Topic 326): Measurement of Credit Losses on Financial Instruments, which replaced the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology.']
New standards
['2016-13']
Prior filed
2026-05-15
Prior form
10-Q
Source
accounting standards update (ASU) reference comparison
Why
The summary of significant accounting policies changed materially from the previous comparable filing.

Source filing ↗ Prior filing ↗